203 related articles for article (PubMed ID: 22180392)
1. Dynamic contrast-enhanced magnetic resonance imaging as a prognostic factor in predicting event-free and overall survival in pediatric patients with osteosarcoma.
Guo J; Reddick WE; Glass JO; Ji Q; Billups CA; Wu J; Hoffer FA; Kaste SC; Jenkins JJ; Ortega Flores XC; Quintana J; Villarroel M; Daw NC
Cancer; 2012 Aug; 118(15):3776-85. PubMed ID: 22180392
[TBL] [Abstract][Full Text] [Related]
2. Dynamic magnetic resonance imaging of regional contrast access as an additional prognostic factor in pediatric osteosarcoma.
Reddick WE; Wang S; Xiong X; Glass JO; Wu S; Kaste SC; Pratt CB; Meyer WH; Fletcher BD
Cancer; 2001 Jun; 91(12):2230-7. PubMed ID: 11413510
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of tumoral and peritumoral magnetic resonance parameters in osteosarcoma patients for monitoring chemotherapy response.
Hao Y; An R; Xue Y; Li F; Wang H; Zheng J; Fan L; Liu J; Fan H; Yin H
Eur Radiol; 2021 May; 31(5):3518-3529. PubMed ID: 33146792
[TBL] [Abstract][Full Text] [Related]
4. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) for pretreatment prediction of neoadjuvant chemotherapy response in locally advanced hypopharyngeal cancer.
Guo W; Zhang Y; Luo D; Yuan H
Br J Radiol; 2020 Nov; 93(1115):20200751. PubMed ID: 32915647
[No Abstract] [Full Text] [Related]
5. Pharmacokinetic parameters from 3-Tesla DCE-MRI as surrogate biomarkers of antitumor effects of bevacizumab plus FOLFIRI in colorectal cancer with liver metastasis.
Hirashima Y; Yamada Y; Tateishi U; Kato K; Miyake M; Horita Y; Akiyoshi K; Takashima A; Okita N; Takahari D; Nakajima T; Hamaguchi T; Shimada Y; Shirao K
Int J Cancer; 2012 May; 130(10):2359-65. PubMed ID: 21780098
[TBL] [Abstract][Full Text] [Related]
6. Assessing vascular effects of adding bevacizumab to neoadjuvant chemotherapy in osteosarcoma using DCE-MRI.
Guo J; Glass JO; McCarville MB; Shulkin BL; Daryani VM; Stewart CF; Wu J; Mao S; Dwek JR; Fayad LM; Madewell JE; Navid F; Daw NC; Reddick WE
Br J Cancer; 2015 Nov; 113(9):1282-8. PubMed ID: 26461056
[TBL] [Abstract][Full Text] [Related]
7. [Predictive value of quantitative dynamic contrast-enhanced magnetic resonance imaging for the efficacy of neoadjuvant chemotherapy in locally advanced gastric cancer].
Zhu YJ; Li Y; Jiang J; Zhang W; Xue LY; Zhou AP; Jiang LM
Zhonghua Zhong Liu Za Zhi; 2019 Oct; 41(10):765-770. PubMed ID: 31648499
[No Abstract] [Full Text] [Related]
8. The cause and clinical significance of central tumor photopenia on thallium scintigraphy of pediatric osteosarcoma of the extremity.
McCarville MB; Barton EH; Cameron JR; Xiong X; Daw NC; Kaste SC; Wu S; Glass JO; Reddick WE
AJR Am J Roentgenol; 2007 Feb; 188(2):572-8. PubMed ID: 17242270
[TBL] [Abstract][Full Text] [Related]
9. Early changes in functional dynamic magnetic resonance imaging predict for pathologic response to neoadjuvant chemotherapy in primary breast cancer.
Ah-See ML; Makris A; Taylor NJ; Harrison M; Richman PI; Burcombe RJ; Stirling JJ; d'Arcy JA; Collins DJ; Pittam MR; Ravichandran D; Padhani AR
Clin Cancer Res; 2008 Oct; 14(20):6580-9. PubMed ID: 18927299
[TBL] [Abstract][Full Text] [Related]
10. [Application on the quantitative perfusion parameters of dynamic contrast-enhanced MRI in the pathological subtype of uterine leiomyoma].
Zheng J; Zhao ZH; Yang JF; Zhao L; Yang LM; Hu HJ
Zhonghua Yi Xue Za Zhi; 2017 Apr; 97(15):1155-1159. PubMed ID: 28427122
[No Abstract] [Full Text] [Related]
11. Dynamic contrast-enhanced MR imaging pharmacokinetic parameters as predictors of treatment response of brain metastases in patients with lung cancer.
Kuchcinski G; Le Rhun E; Cortot AB; Drumez E; Duhal R; Lalisse M; Dumont J; Lopes R; Pruvo JP; Leclerc X; Delmaire C
Eur Radiol; 2017 Sep; 27(9):3733-3743. PubMed ID: 28210799
[TBL] [Abstract][Full Text] [Related]
12. Early responses assessment of neoadjuvant chemotherapy in nasopharyngeal carcinoma by serial dynamic contrast-enhanced MR imaging.
Zheng D; Yue Q; Ren W; Liu M; Zhang X; Lin H; Lai G; Chen W; Chan Q; Chen Y
Magn Reson Imaging; 2017 Jan; 35():125-131. PubMed ID: 27587228
[TBL] [Abstract][Full Text] [Related]
13. Introducing a New Biomarker Named R2*-BOLD-MRI Parameter to Assess Treatment Response in Osteosarcoma.
Kim CH; Lee JH; Lee JW; Kim E; Choi SH
J Magn Reson Imaging; 2022 Aug; 56(2):538-546. PubMed ID: 34888987
[TBL] [Abstract][Full Text] [Related]
14. Development and external validation of nomograms predicting distant metastases and overall survival after neoadjuvant chemotherapy and surgery for patients with nonmetastatic osteosarcoma: A multi-institutional study.
Ogura K; Fujiwara T; Yasunaga H; Matsui H; Jeon DG; Cho WH; Hiraga H; Ishii T; Yonemoto T; Kamoda H; Ozaki T; Kozawa E; Nishida Y; Morioka H; Hiruma T; Kakunaga S; Ueda T; Tsuda Y; Kawano H; Kawai A
Cancer; 2015 Nov; 121(21):3844-52. PubMed ID: 26194185
[TBL] [Abstract][Full Text] [Related]
15. Assessing the Prognostic Significance of Histologic Response in Osteosarcoma: A Comparison of Outcomes on CCG-782 and INT0133-A Report From the Children's Oncology Group Bone Tumor Committee.
Bishop MW; Chang YC; Krailo MD; Meyers PA; Provisor AJ; Schwartz CL; Marina NM; Teot LA; Gebhardt MC; Gorlick R; Janeway KA; Chou AJ
Pediatr Blood Cancer; 2016 Oct; 63(10):1737-43. PubMed ID: 27128693
[TBL] [Abstract][Full Text] [Related]
16. Volume fractions of DCE-MRI parameter as early predictor of histologic response in soft tissue sarcoma: A feasibility study.
Xia W; Yan Z; Gao X
Eur J Radiol; 2017 Oct; 95():228-235. PubMed ID: 28987672
[TBL] [Abstract][Full Text] [Related]
17. Pancreatic cancer: utility of dynamic contrast-enhanced MR imaging in assessment of antiangiogenic therapy.
Akisik MF; Sandrasegaran K; Bu G; Lin C; Hutchins GD; Chiorean EG
Radiology; 2010 Aug; 256(2):441-9. PubMed ID: 20515976
[TBL] [Abstract][Full Text] [Related]
18. Multiinstitutional phase II study of neoadjuvant chemotherapy for osteosarcoma (NECO study) in Japan: NECO-93J and NECO-95J.
Iwamoto Y; Tanaka K; Isu K; Kawai A; Tatezaki S; Ishii T; Kushida K; Beppu Y; Usui M; Tateishi A; Furuse K; Minamizaki T; Kawaguchi N; Yamawaki S
J Orthop Sci; 2009 Jul; 14(4):397-404. PubMed ID: 19662473
[TBL] [Abstract][Full Text] [Related]
19. Role of dynamic MRI and clinical assessment in predicting histologic response to neoadjuvant chemotherapy in bone sarcomas.
Amit P; Patro DK; Basu D; Elangovan S; Parathasarathy V
Am J Clin Oncol; 2014 Aug; 37(4):384-90. PubMed ID: 23388556
[TBL] [Abstract][Full Text] [Related]
20. Tumor size as a predictor of outcome in pediatric non-metastatic osteosarcoma of the extremity.
Kaste SC; Liu T; Billups CA; Daw NC; Pratt CB; Meyer WH
Pediatr Blood Cancer; 2004 Dec; 43(7):723-8. PubMed ID: 15390310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
